---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-26-000036"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:43:35.816883+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q1 revenue $200.4M, GAAP net loss $34.1M; reiterates FY guidance

## Summary
- GAAP net loss $34.1M ($0.36/sh); adjusted loss $0.09/sh; adjusted EBITDA negative $4.5M.
- Revenue $200.4M (+2% YoY); Cancer Care +4%, Prenatal -15%, Mental Health +24%.
- Test volumes 385k flat YoY; Cancer Care +13%, Prenatal -12%, Mental Health +7%.
- Launched Precise MRD (ultrasensitive assay) and received FDA approval for MyChoice CDx as Zejula companion diagnostic.
- Reiterated FY 2026 guidance: revenue $860-880M, adjusted EBITDA $37-49M, adj. gross margin 68-69%.

## SEC filing metadata
- accession: 0000899923-26-000036
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992326000036/0000899923-26-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992326000036/mygn-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-26-000036
- JSON: https://secwatch.observer/filing/0000899923-26-000036.json
- Plain text: https://secwatch.observer/filing/0000899923-26-000036.txt

## Key facts
- Earnings Releases
  MYRIAD GENETICS INC reported first quarter ended March 31, 2026 results: revenue 200.4 million, net income net loss of $34.1 million, EPS loss per share was $0.09 per share. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2026
  - Revenue: 200.4 million
  - Net income: net loss of $34.1 million
  - EPS: loss per share was $0.09 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test.
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992326000036/0000899923-26-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.